nab-paclitaxel

  • October 26, 2020  

    How an Expert Would Manage His Own Stage 4 Pancreatic Cancer

    With: John H. Strickler, MD

    When confronted with a new cancer diagnosis, some people ask their doctors, “What would you do if you were me?” Here, our Curious Dr. George asks Cancer Commons Expert Physician Advisor John Strickler, MD, how he would handle his own diagnosis of metastatic pancreatic cancer. Dr. Strickler is Associate Professor of Medicine in the Division of Medical Oncology at Duke University and Co-Leader of… Read more »

  • April 8, 2019  

    Atezolizumab/Nab-Paclitaxel Approved by the FDA for PD-L1+ TNBC Bookmark

    Emma Shtivelman, PhD

    Excerpt:

    “An accelerated approval has been granted by the FDA for the combination of atezolizumab (Tecentriq) and nab-paclitaxel (Abraxane) as a frontline treatment for patients with unresectable locally advanced or metastatic PD-L1–positive triple-negative breast cancer (TNBC).

    “The approval is based on the phase III IMpassion130 trial, in which the addition of the PD-L1 inhibitor atezolizumab to nab-paclitaxel reduced the risk of progression or death by 40% compared with nab-paclitaxel alone in this patient population.”

    Go to full article published by Targeted Oncology on March 8, 2019.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • August 5, 2018  

    Atezolizumab Plus Chemotherapy Improves PFS for Triple-Negative Breast Cancer Bookmark

    Emma Shtivelman, PhD

    Excerpt from Healio:

    “First-line atezolizumab plus nab-paclitaxel improved PFS compared with placebo among patients with metastatic or unresectable locally advanced triple-negative breast cancer, according to interim results from the IMpassion130 trial released by the manufacturer.

    “Researchers observed prolonged PFS in both the intention-to-treat population and the PD-L1-positive population.”

    Go to full article published by Healio on July 2, 2018.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.